Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment
Silke Polsfuß, Sabine Hofmann-Thiel, Matthias Merker, David Krieger, Stefan Niemann, Holger Rüssmann, Nicolas Schönfeld, Harald Hoffmann, et al. (9 authors)
Clinical Infectious Diseases · 2019-01
Abstract
Abstract Two new drugs, delamanid and bedaquiline, have recently been approved for treatment of multidrug-resistant and extensively drug-resistant (XDR) tuberculosis. Here, we report a case of clofazimine, bedaquiline, and low-level delamanid resistances acquired during treatment of a patient with XDR tuberculosis.
MeSH terms
- Bedaquiline
- Medicine
- Tuberculosis
- Drug resistance
- Drug
- Drug resistant tuberculosis
- Intensive care medicine